אוניברסיטת בר-אילן והפקולטה למדעי החיים ע”ש מינה ואבררד גודמן שמחים להזמינכם
לכנס בר-אילן לעידוד שת”פ עם התעשייה
כנס בר אילן לעידוד שתפ עם התעשייה
פרופ’ שי רהימיפור מהמחלקה לכימה באוניברסיטת בר-אילן פיתח מוצר כימי המאפשר להצמיד חומר מועיל למשטחים. החומר יאפשר לייצר צבעים קוטלי חיידקים, משחקי ילדים המונעים העברת מחלות, תחבושות היגיניות המונעות ריח, פלסטרים מחטאים ועוד – חומרים שבהם נדרשת גם הצמדה חזקה ויציבה למשטח, וגם תכונות כימיות מועילות.
“החומר הזה אינו המצאה מקורית שלנו” מודה פרופ’ רהימיפור. “הוא מבוסס על תצפיות בתכונה מופלאה של בעל חיים קטן שכולנו מכירים”. התכונה הזו נחקרה כבר בעבר ע״י מדענים אחרים, והחומר הגורם לה בודד ואופיין. צוות חוקרים בצוות של פרופ׳ רהימיפור המציאו שיטה חדשה ויעילה מאוד להכין חלקיקים ננומטרים של החומר – ואלה משחזרים את היכולת של בעל החיים להיצמד למשטחים שונים. יחד עם זאת, תכננו החוקרים את המולקולה של החומר בדרך המאפשרת להעשיר אותו בקלות במגוון רחב של תכונות שימושיות חדשות – תכונות שבעל החיים בטבע אינו צריך כלל.
“תארו לכם, למשל, שאנו מציעים ליצרן צבעים תוסף לצבע שבזכותו חיידקים הנוחתים על הקיר הצבוע נקטלים מייד. הקיר הצבוע שומר על התכונה הזו חודשים ארוכים, ואפילו שנים” אומר פרופ’ רהימיפור כשהוא מתכוון לצביעה של קירות בבתי חולים, ריהוט בגני ילדים, או חדרים בבתי ילדים ובמעונות.
ד”ר פרנסיס שליט, סמנכ”לית לפיתוח עסקי בביראד (החברה הממונה על מיסחור ההמצאות של אוניברסיטת בר-אילן) מסבירה את החשיבות של ההמצאה: “קיימים בשוק עוד צבעים כאלה, הנקראים ‘אנטי-בקטריאליים’, אבל החומר של שי זול מהם בסדר גודל, פי שלוש קטלני מהם, פי שבע פחות רעיל לבני אדם, משמר את היכולת הזו הרבה יותר זמן (חודשים ושנים) ומכסה מספר רב של סוגי חיידקים”. ד”ר שליט משוכנעת שתעשיות רבות ירצו להוסיף את החומר הזה למוצרים שלהן ולזכות בתכונות חשובות בעלות נמוכה.
ביראד התחילה כבר את נסיונות השיווק של הרישיון לחומר הזה – בשלב זה בוחנים את החומר מפעלים ישראליים המפתחים תחבושות ופדים ומפעלים המפתחים צבעים לשימוש תעשייתי וביתי. בהמשך תרחיב האוניברסיטה את היישומים של החומר לתחומים תעשייתיים נוספים ולשוק הבינלאומי.
“הטבע מלמד אותנו חלק מחוכמתו” אומר פרופ’ רהימיפור בחיוך. “והמזל שלנו הוא שהטבע אינו רושם פטנטים על המצאותיו ומאפשר לחוקרים לבסס המצאות חדשות על התבונה שלו. על המצאות אלו ניתן לרשום פטנטים ואז להעניק רשיונות לתעשייה”.
ביראד תרצה לשקול יישומים נוספים לחומר הזה – מצבים שבהם קיים חומר בעל יכולת מועילה מאוד, וצריך דרך להצמיד אותו למשטחים כך שיישאר צמוד למשטח וישחרר את החומר המועיל לאט לאט, לאורך שנים.
לפרטים : מירב בורשטיין. 077-3643534, 052-2229330. Merav@birad.biz
Professor Orit Shefi, head of BIU’s Neuro-Engineering and Regeneration Laboratory, in Bar-Ilan’s Faculty of Engineering, has invented a method to dramatically enhance the healing of damage stemming from transected nerves. Successful repair of a transected nerve can restore sensory perception and functional recovery to limbs paralyzed in an accident or an injury. This invention has been recently registered as an international patent, through BIRAD – Research & Development Company Ltd, Bar-Ilan University’s commercializing company.
The regenerating process of a transected nerve is similar to the process of repairing a torn water pipe: a different nerve autograft or a conduit made of elastic material (for e.g. Collagen gel which is natural for the body) is implanted and very carefully connected to both nerve endings (a gap is often created between the two nerve endings due to the injury, and the conduit bridges this gap). Neuron cells from the connected side of the cell (the one leading from the brain) start to advance inside the conduit towards the disconnected part of the nerve and to the damaged organ. When the nerve cells reach the target organ, neuronal activity begins through the conduit and the regenerated nerve. Implanting the conduit and connecting it at both ends is surgically performed.
A full or empty conduit? In order for the nerve cells to advance along the conduit, it may be beneficial to fill the conduit with a substance that is ready to host the nerve cells and enable them to advance and provide support. This substance can also be based on Collagen fibers. The nerve cells advance along the Collagen fibers relying on them as physical cues. This is precisely the problem – filling the conduit with a biomimetic material is a challenge that many labs are trying to solve – which professor Shefi has solved through her invention:
If the conduit is implanted when it’s full of Collagen and the fibers are aligned with the conduit’s direction – it’s easy for the nerve cells (since they know where to advance), but difficult for the surgeon. Imagine a plumber who has to connect two pipes using a piece of pipe full of water, without spilling the water.
If the conduit is implanted when it’s empty, and the Collagen is injected into it as a gel consisting of messy fibers after it’s connected – it’s easy for the surgeon, and difficult for the nerve cells: they have to make their way through entangled fibers which do not point in the right direction. They have to reach an unfamiliar destination with no map or Waze. In other words – the regeneration and healing process will be extremely lengthy.
So which do we prefer? A difficult dilemma – will we prefer a simple operation and a lengthy recovery, or a complicated operation and a short recovery? “We’ll prefer one and the other” says Prof. Orit Shefi, “A simple operation with an empty conduit, and directed fibers which conduct the nerve cells directly to the other end of the conduit”. Our invention enables this vision in a way that can be explained simply: “We will create a gel with magnetic substance in it” she explains, “We’ll connect the nerve endings to the empty conduit. We’ll inject this gel into the conduit. It will remain liquified for a few minutes, and then coagulate. During those few minutes, we’ll keep a strong magnet pointed in the right direction next to the body. All the Collagen fibers will align according to the magnet. We’ll hold the magnet until the gel solidifies and its fibers are aligned. We will dispose of the magnet, and the fibers will remain pointing in the right direction.”
This invention is patent protected, and using it surgeons will be able to revive paralyzed limbs,” says the researcher Merav Antman Passig who’s dissertation was conducted in this research, “and maybe, in the future, a paralyzed body as well.” It will happen if the procedure will be able to connect a severed spinal cord using the gel. This option is unavailable today, and Merav hopes that if the invention will be developed into a medicinal product, in the future, people with upper-limb paralysis will be able to move their hand and wave their appreciation to the university and to science.
Dr. Frances Shalit, Senior VP of Business Development in BIRAD, states: “We have already begun looking for a company that is suitable for implementing the invention, and BIRAD, naturally, reaches out initially to companies which manufacture solutions for neuro connectivity. Every business factor that wants to take part in completing the research and to own rights of the invention, is welcome to reach out to Birad and take an interest.”
For further details: Merav Burstein 972-77-3643534, 972-52-2229330 Merav@biraz.biz
The Israeli Isotopia Company, in collaboration with Prof. Rachela Popovtzer of Bar-Ilan University, is conducting a joint study to develop a radioactive marker, based on nanoparticles, for the detection of cancer. The goal of this research is to facilitate, for the first time, the distinction between tumors and inflammation.
The most common imaging method for diagnosing and monitoring cancer today is the positron emission tomography (PET) scan used with radioactive contrast material fluorodeoxyglucose (FDG). But FDG gives high rates of false positives, which lead to false therapeutic observations and expensive costs for health care systems. The main problem is that the test can detect not only tumors, but also inflammation, making it difficult to differentiate between cancerous growths and inflammation.
The material being developed by the researchers is a radioactive contrast agent based on nanoparticles. In addition to identifying, imaging and tracking cancer tumors, these nanoparticles make it possible to make an unequivocal distinction between tumor and inflammation.
“The technology we are developing is significant because it will enable physicians to make a better diagnosis,” said Dr. Eli Shalom, CEO of Isotopia Molecular Imaging. “Another advantage is that it will be used in existing PET/CT centers and rely on equipment that’s already in place, so it’s very economical.”
Dr. Shalom said that the vision in this development is far beyond specific cancer identification. “The method we are developing can be combined with Lu177 for therapy as well as the imaging. This is an innovative field called Theranostics (therapy + diagnostics). In the Theranostics model, we use the same molecules and radiolabel them for imaging and therapy each time with a different isotope. “. Isotopia, which today focuses on the development of Theranostic products for prostate cancer, will be an excellent platform for bringing development to the Global market
The research is being carried out within the framework of the “Magneton” program of the “Innovation Authority” (formerly the “Bureau of the Scientist”), which funds research aimed at encouraging the transfer of technological know-how accumulated in academia for innovative industry products. Fundraising for Magneton (for Bar-Ilan University) was overseen by Birad Research and Development Company Ltd.”.
Isotopia, the nuclear pharmacy with knowledge and experience in the radiochemical connection, has extensive experience in developing processes and applying them for molecular imaging. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers and physicists.
The experienced Isotopia team, together with its radio-nuclear pharmacy and cyclotron facility, are a well-established platform for development. Isotopia conducts research and development initiatives in cooperation with leading medical centers and with leading research laboratories in Israel. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy. Isotopia develops strategic partnerships in procurement, production and international sales of Isotopes in the manufacture of cyclotron, radio-pharmaceuticals and related molecular imaging technologies, as well as new developments in the field of radiotherapy.
About Birad – Research & Development Company Ltd. The commercializing company of Bar-Ilan University, which promotes collaborations, corporations and alliances to manage the intellectual property, and technology commercialization by creating risk and licensing, promoting scientific service agreements through the technological knowledge and infrastructure of the University for the benefit of members of the industrial community, and outsourcing services for the business sector as part of the Division of Scientific Services.
For more information: Merav Burstein. Tel: 0773643534. Merav@birad.biz
As part of the program, CogniFiber will be mentored by experts from Intel’s business organizations, will be exposed to state-of-the-art technology, along with an educational infrastructure and local and international events.
CogniFiber has been chosen to participate in the fourth cycle of Intel’s prestigious program for leveraging startups. The program’s framework is based on a demo and POC which is built on defining joint project goals for CogniFiber and Intel. The company will gain mentoring by experts from Intel’s business organizations, will be exposed to state-of-the-art technology, together with an educational infrastructure and local and international events.
Cognifiber is a leader in the field of photonic computing, the emerging technology of the next decades. The primary development of the technology on which the company was founded was done by Dr. Eyal Cohen, who performed a post-doctorate research in the laboratory of Prof. Zeev Zalevsky, from the Faculty of Engineering, in Bar-Ilan university in collaboration with Dr. Mickey London from The Interdisciplinary Center for Neural Computation (ICNC), The Hebrew University of Jerusalem, as an additional advisor. Dr. Eyal Cohen approached the two with a proposal to carry out the research and with Prof. Zalevsky’s extensive experience, promoted the research and its commercialization through BIRAD, Research & Development company Ltd. and the Deputy President of Bar-Ilan university.
Dr. Eyal Cohen together with Prof. Zalevsky and Ms. Keren Levy, who served as a business advisor for the company, co-founded the company. Dr. Eyal Cohen, acts as the leading entrepreneur and company CEO, Prof. Zeev Zalevsky is the company CTO and Keren Levy acts as the company COO.
CogniFiber implements advanced algorithms such as machine learning and deep learning neural networks within unique optic fibers, which enable up to 10,000x acceleration in computation rate, coupled with a staggering 10x-100x reduction in power consumption and heat dissipation, at these computation rates. CogniFiber’s photonic devices will not only revolutionize the world of AI and computing, but will also make AI cheaper, more mobile and more accessible. In-fiber photonic computing devices can deliver a solution for the ever-growing processing needs, they are easy to manufacture, scalable, fault-resistant, and could be connected to any existing communication platform.
Intel’s IPP program is open (every cycle) for about 10 companies and offers them 6-8-months of professional mentoring framework to improve their technology and products, while leveraging on Intel’s technological resources, global presence, and vast network of business connections, in preparation for a successful market penetration. The program is in collaboration with Intel Capital, one of the world’s biggest Venture Capitals, which enables entrepreneurs direct access to this track.
The IPP program, which began operating in 2015, has accompanied about 30 companies, which raised a total of 281 million dollars between them in the past three years. 93% of the companies are still active, and Intel does not demand or take equity or percentages.
With the purchase of Mobileye, Replay, and positioning Intel as a data company, Intel is without a doubt a central player in all emerging and exciting technologies of today’s industry and acts as an excellent source for entrepreneurs who want to accelerate their product or technology.
Birad – Research & Development Company Ltd. the commercializing company of Bar-Ilan University, which promotes innovative technology commercialization, invented by university researchers, encourages scientists to promote their researches and expand them towards industrial and implementational initiatives.
Additional details at the company’s site: www.birad.biz
For additional info regarding CogniFiber: http://www.cognifiber.com
For additional details: Merav Burstein – 052-2229330 – email@example.com
Nano-Drops May Offer New Alternative to Current Methods of Vision Correction
Ramat Gan, Israel — A revolutionary, cutting-edge technology, developed by researchers at Bar-Ilan University’s Institute of Nanotechnology and Advanced Materials (BINA), has the potential to provide a new alternative to eyeglasses, contact lenses, and laser correction for refractive errors.
The technology, known as Nano-Drops, was developed by Dr. David Smadja (Ophthalmologist from Shaare Zedek Medical Center), Prof. Zeev Zalevsky, from Bar-Ilan’s Kofkin Faculty of Engineering, and Prof. Jean-Paul Moshe Lellouche, Head of the Department of Chemistry at Bar-Ilan. A related patent on this new invention was recently filed by Birad – Research & Development Company Ltd., the commercializing company of Bar-Ilan University. Steve Elbaz is a Co-Founder and Chief Business Officer of the new technology.
Nano-Drops achieve their optical effect and correction by locally modifying the corneal refractive index. The magnitude and nature of the optical correction is adjusted by an optical pattern that is stamped onto the superficial layer of the corneal epithelium with a laser source. The shape of the optical pattern can be adjusted for correction of myopia (nearsightedness), hyperopia (farsightedness) or presbyopia (loss of accommodation ability). The laser stamping onto the cornea takes a few milliseconds and enables the nanoparticles to enhance and ‘activate’ this optical pattern by locally changing the refractive index and ultimately modifying the trajectory of light passing through the cornea.
The laser stamping source does not relate to the commonly known ‘laser treatment for visual correction’ that ablates corneal tissue. It is rather a small laser device that can connect to a smartphone and stamp the optical pattern onto the corneal epithelium by placing numerous adjacent pulses in a very speedy and painless fashion. Tiny corneal spots created by the laser allow synthetic and biocompatible nanoparticles to enter and locally modify the optical power of the eye at the desired correction.
In the future this technology may enable patients to have their vision corrected in the comfort of their own home. To accomplish this, they would open an application on their smartphone to measure their vision, connect the laser source device for stamping the optical pattern at the desired correction, and then apply the Nano-Drops to activate the pattern and provide the desired correction.
Upcoming in-vivo experiments in rabbits will allow the researchers to determine how long the effect of the Nano-Drops will last after the initial application. Meanwhile, this promising technology has been shown, through ex-vivo experiments, to efficiently correct nearly 3 diopters of both myopia and presbyopia in pig eyes.
Company recognized for its development by Bar-Ilan University engineering professor of a biometric sensing system that detects biomedical parameters from a distance without human contact
Israeli start-up ContinUse Biometrics is among the ten first-place winners of the prestigious 2018 Prism Award (the Oscar of the photonics industry) for the Medical and Health category. The company is being recognized for its invention of an optical sensing system (sensory camera) in a competition sponsored by Photonics and SPIE Media This is the tenth year that the competition has been held.
“We chose the ten companies that introduced the greatest innovation and creativity in their products and showed impressive data and performance in every possible parameter. These are inventions that, without a doubt, advance the photonics industry and its prosperity,” noted the organizers of the competition.
ContinUse Biometrics took first place for its laser-based detector and camera that remotely and accurately identify nanoscale movements. The sensor is aimed at the subject, enabling accurate physiological data to be obtained.
ContinUse Biometrics focuses on developing novel devices for the health field in general and preventive medicine in particular — for use in the home, the vehicle, the workplace and the clinic. Its products enable ongoing monitoring of vital indicators and patients suffering from chronic diseases such as heart disease, respiratory diseases, and more.
The products developed by ContinUse Biometrics is ideal for senior citizens by virtue of the fact that it transfers medical care from the doctor’s office to the home environment and alerts medical professionals to any change in vital indicators. The attending physician receives all the readings remotely and provides appropriate medical instructions to the patient. This Telemedicine platform has the potential to minimize visits to clinics and/or hospitalization, while monitoring the patient in his own home in a comfortable, non-contact environment and increased level of service.
The detector is based on the development of Bar-Ilan University engineering professor Zeev Zalevsky, Chief Technology Officer of ContinUse Biometrics. . The detector identifies several groups of physiological parameters including vital signs such as heartbeat,, breathing and blood pressure; allows for listening to heart and breathing sounds (much like a stethoscope); identifies changes in peripheral blood flow patterns; identifies hematologic parameters; identifies people according to their heart tone; and provides muscle and bone measurements including changes in muscle tone and detection of fractures. All measurements are conducted remotely, with no human contact.
The response of medical markets to this development has been most enthusiastic, and the business potential is estimated at hundreds of millions of dollars. In addition, the company plans to activate the sensor in clinics and operating rooms. In this framework, the company will perform several hospital clinical trials over the coming year.
ContinUse Biometrics was founded by CEO Asher Polani with assistance from Bar-Ilan University’s BIRAD Research and Development Company Ltd., which promotes the commercialization of innovative technologies invented by university researchers, and encourages scientists to advance and expand their research with an eye toward industrial applications.
For further information, contact: Merav Burstein, BIRAD Research and Development Company Ltd., 077-3643534, 052-2229330, Merav@birad.biz
Dr. Beena Kalisky, from the Department of Physics and Bar Ilan’s Institute for Nanotechnology and Advanced Materials, together with researchers from France, Italy, the Netherlands, Spain and Sweden, are developing Quantum Technology using 2D interfaces created between oxides as part of the QUANTOX project (QUANtum Technologies with 2D-Oxides).
The research is budgeted by QuantERA, a European Research Fund, that brings together 31 research funding agencies from 26 countries, coordinated by the National Science Centre in Poland, and the Israel Innovation Authority (formerly known as “The Chief Scientist”).
Developing a quantum computer is one of the most desirable objectives today, and researches in the field are supported by powerful organizations such as Microsoft, Bell Labs, IBM and Google. Quantum computation will have a major effect on the computer’s performance and information security. Developing such a computer first requires the development of a basic memory cell, Qubit, using technology which is topologically protected. Despite the immense technological challenge, the advantage of such computers in speedy calculations and noise resistance, lead the significant investment in research and development of the field.
The proposed approach of the research team of QUANTOX is to use the diverse characteristics of Oxide interfaces to develop Quantum Topological systems that can be easily integrated within the current technology. These interfaces possess a unique combination of physical qualities that according to theoretical forecasts, will enable the implementation of the necessary conditions for developing a basic memory cell.
The development process is both challenging and complex. In this project the challenge is especially significant due to the technological difficulty of measuring phenomena based on minute electrical currents in substances with a 2D flow. The lab headed by Dr. Kalisky, develops highly sensitive sensors for measuring magnetic fields, and use it to map tiny magnetic fields that are generated by a small number of electrons, or very weak electrical currents. The measurement is conducted in Dr. Kalisky’s lab, in a local and non-invasive fashion, allowing feedback for the development process, even before reaching the complex stages of connecting a memory cell to the entire system, and so enabling the development to be focused and accelerated.
Beena: “The highly sensitive magnetic imaging tool which we operate in the lab is very helpful for development stages.. Especially in fields of research conducted at cold temperatures. Exciting quantum physics takes place at temperatures close to the absolute 0 and we are excited to harness our research tools to these major objectives.”
The agreement between the parties was carried out by Birad – Research & Development Company Ltd. the commercializing company of Bar-Ilan University, which promotes collaborations, corporations and alliances to manage the intellectual property, and technology commercialization by creating risk and licensing, promoting scientific service agreements through the technological knowledge and infrastructure of the University for the benefit of members of the industrial community, and outsourcing services for the business sector as part of the Division of Scientific Services.
For additional info: Merav Burstein – 052-2229330 – firstname.lastname@example.org
The Israeli chip consortium, MDM – Multi Dimensional Metrology, which promotes the development of measurement and process control technologies in the chip industry, based on data fusion from many sources, began to operate in September following approval of the Israel Innovation Authority.
The new consortium, established at the initiative of Applied Materials Israel, will include researchers from the Institute for Nanotechnology in the Bar Ilan University: Dr. Yaacov Tischler, Dr. Sharon Shwartz and Dr. Lior Klein who were granted funds totaling 727,419 NIS to carry out their researches. The funds for the MAGNET program to the Bar-Ilan University, were raised by BIRAD – Research and Development Company LTD.
MAGNET is a program sponsored by the Office of the Chief Scientist of the Ministry of Industry, Trade & Labor, which focuses on strengthening the Israeli Industry through funding of research and development collaborations between industrial companies and academic research groups, seeking to develop innovative technologies in different fields. The government is expected to fund about 80% of the academic research budget of the consortium through the Innovation Authority (and the rest from the industrial companies in the consortium) and is expected to operate for 3-5 years.
The chairman of the consortium is Yoram Uziel, Director of Technology at PDC, Applied Materials Metrology Division. The new consortium will include leading companies in the field of process control, such as Nova – a leading innovator and a key provider of metrology solutions for advanced process control used in semiconductor manufacturing, Bruker (which acquired Jordan Valley of Israel), Dell EMC, Nanonics, leader in atomic microscopy measuring solutions, Nanomotion, which develops nanoscale conveyance systems, EL-MUL, from Rehovot, which manufactures detectors for the nanoscale industry.
The academic side will include research groups from the Technion, Hebrew University, Tel Aviv University, the Weizmann Institute, and Ben-Gurion University, which will also provide construction services for nanoscale structures.
About BIRAD – Research & Development Company Ltd.
BIRAD, established in 1974, was founded in order to commercialize the academic knowledge of the Bar-Ilan University. The company offers collaborations, corporations and alliances to manage the intellectual property, technology commercialization by creating risk and licensing, promotion of scientific service agreements through the technological knowledge and infrastructure of the University for the benefit of the members of the industrial community, and outsourcing services for the business sector as part of the Division of Scientific Services. The company has access to facilities for life sciences, Nanotechnology, chemistry and other fields of research. The company collaborates with the Institute for Nanotechnology and the Faculty of Medicine in the Galilee, and has signed collaboration agreements with international companies such as Samsung, BASF, GM, EMC, and more.
For additional info: Merav Burstein:, cell: 972-52-2229330, email: email@example.com
The HiPer Consortium SoC Lab of Bar Ilan University, together with its partners, Cadence Design Systems, imec and TSMC, announced today the successful bring-up and validation of its 28nm system-on-chip (SoC) platform, which provides a foundation for collaborative innovation in advanced process nodes.
The SoC Lab, funded by the Magnet Program of the Israel Innovation Authority in the framework of the HiPer Consortium, was established to address multiple challenges of SoC design. This is Israel’s first scaled SoC design, implementation and measurement laboratory that ties academic research to industrial requirements.
The 28nm SoC is the HiPer SoC Lab’s first project and the fruition of extensive design effort and collaboration, covering all the design aspects from architecture definition to silicon validation. It integrates complex digital and analog intellectual property (IP) such as control processor, network-on-chip (NOC) interconnect fabric and advanced analog front-end (AFE). This platform is used to characterize and test new developments in a system level environment, as well as to develop and practice advanced design flows and methodologies. This project sets the infrastructure for future collaborative industry-academia SoC-related research and development in scaled process nodes.
The 28nm SoC project is the result of a unique partnership and close collaboration between the HiPer SoC Lab and major players in the semiconductor industry ecosystem.
“We appreciate the contributions from all of our industry partners to the success of the SoC Lab”, said Professor Alexander Fish at Bar-Ilan University. “We are looking forward to continue and further develop this unique academia-industry cooperation in our next projects”.
The design and verification know-how that was gathered during this project, along with the IP validated upon the SoC platform, will be used by the Israeli microelectronics industry for commercial products.
Cadence, via its Cadence Academic Network, supported the tapeout by providing licenses of its Cadence® digital and signoff solutions. Additionally, Cadence Design IP, such as Ethernet Controller and PHY, were integrated in the design. For the hardware/software co-verification, the Cadence Palladium® hardware emulator platform was deployed. During the tapeout phase, the company offered their extensive engineering expertise. The combination of the company’s software, services, Design IP and Palladium platform enabled the first-time-right silicon success.
“The HiPer Consortium project is a fantastic example of how academia and industry can work together and exchange expertise to support design innovations,” said Sanjay Lall, Vice President of Worldwide Field Operations for Cadence EMEA. “With this success, the Israeli microelectronics industry has received an important platform to address advanced SoC design. We are excited to be part of the next projects with our collaboration partners.”
Cadence, the world-leading research and innovation hub in nanoelectronics and digital technologies, provided the foundry tapeout support and low-cost prototyping services through its imec.IC-link program.
“imec.IC-link is proud to be part of this HiPer SoC Lab initiative. In a spirit of collaborative innovation, HiPer is bridging the gap between academia and industry. The accumulated experience will lower the barrier for startups and SME’s, to gain access to advanced ASIC technology”, said Steve Beckers, VP at imec and GM of imec.IC-link.
TSMC, the world’s largest dedicated semiconductor foundry, provided access to its 28nm HPM process technology design kit, including standard cell libraries, memory compilers, I/O libraries and provided foundry services.
“I congratulate the HiPER consortium on the successful launch of its design Platform, which offers new designers a fast route to silicon success”, said Maria Marced, President TSMC Europe. “This design platform will showcase the innovation of the Israeli design community. As the world’s leading semiconductor foundry, TSMC is happy to offer our technology leadership as well as manufacturing excellence, and we look forward to further close collaboration.”
About HiPer Consortium
The HiPer consortium is involving industrial companies and academic research to push the VLSI/SoC performance boundaries and achieve a much better, cheaper and faster R&D process and chips. The HiPer consortium has set the following long term strategic goals:
To achieve the above goals, the HiPer consortium is conducting cutting edge R&D work in the following technological areas:
More information about the Hiper consortium is available at www.hiper.org.il
Cadence enables electronic systems and semiconductor companies to create the innovative end products that are transforming the way people live, work and play. Cadence software, hardware and semiconductor IP are used by customers to deliver products to market faster. The company’s System Design Enablement strategy helps customers develop differentiated products—from chips to boards to systems—in mobile, consumer, cloud datacenter, automotive, aerospace, IoT, industrial and other market segments. Cadence is listed as one of Fortune Magazine’s 100 Best Companies to Work For. Learn more at www.cadence.com
Imec is the world-leading research and innovation hub in nanoelectronics and digital technologies. The combination of our widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes us unique. By leveraging our world-class infrastructure and local and global ecosystem of partners across a multitude of industries, we create groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy.
As a trusted partner for companies, start-ups and universities we bring together close to 3,500 brilliant minds from over 75 nationalities. Imec is headquartered in Leuven, Belgium and also has distributed R&D groups at a number of Flemish universities, in the Netherlands, Taiwan, USA, China, and offices in India and Japan. In 2016, imec’s revenue (P&L) totaled 496 million euro. Further information on imec can be found at www.imec.be
Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a “stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Government), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre which is supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.) and imec China (IMEC Microelectronics (Shanghai) Co. Ltd.) and imec India (Imec India Private Limited), imec Florida (IMEC USA nanoelectronics design center).
TSMC is the world’s largest dedicated semiconductor foundry, providing the industry’s leading process technology and the foundry segment’s largest portfolio of process-proven libraries, IPs, design tools and reference flows. The Company’s owned capacity in 2017 is expected to reach above 11 million (12-inch equivalent) wafers, including capacity from three advanced 12-inch GIGAFAB® facilities, four eight-inch fabs, one six-inch fab, as well as TSMC’s wholly owned subsidiaries, WaferTech and TSMC China. TSMC is the first foundry to provide both 20nm and 16nm production capabilities. Its corporate headquarters are in Hsinchu, Taiwan. For more information about TSMC please visit http://www.tsmc.com.